Clinical Trial

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-04-10; most recent amendment 2026-06-26.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-05-23
Trial Details
NCT Number NCT06926621
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Myotonic Dystrophy Type 1 (DM1)
Enrollment 44 participants
Start Date 2025-04-28
Primary Completion 2029-01-30 (estimated)
Study Completion 2029-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10